CR11576A - Compuestos de 1,2, 4-oxadiazol para el tratamiento de enfermedades autoinmunes - Google Patents
Compuestos de 1,2, 4-oxadiazol para el tratamiento de enfermedades autoinmunesInfo
- Publication number
- CR11576A CR11576A CR11576A CR11576A CR11576A CR 11576 A CR11576 A CR 11576A CR 11576 A CR11576 A CR 11576A CR 11576 A CR11576 A CR 11576A CR 11576 A CR11576 A CR 11576A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- treatment
- formula
- pharmaceutically acceptable
- autoimmune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se relaciona con derivados novedosos de oxadiazol de formula (I) o una sal farmaceuticamente aceptables de los mismos, compuestos de formula (I), y sus sales farmaceuticamente aceptables son de uso en el tratamiento de condiciones o transtornos que son mediados via el receptor S1P1; en particular los compuestos de f÷rmula (I) y sus sales farmaceuticamente aceptables son de uso en el tratamiento de la esclerosis multiple, enfermedades autoinmunes, trastornos inflamatorios cronicos, asma, neuropatias inflamatorias, atritis, transplante, enfermedad de Crohn, colitis ulcerativa, lupus eritematoso, soriasis, enfermedades vasculares, diabetes dependiente y no dependiente de la insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0725102.8A GB0725102D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
PCT/EP2008/067972 WO2009080730A1 (en) | 2007-12-21 | 2008-12-19 | 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11576A true CR11576A (es) | 2010-09-03 |
Family
ID=39048652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11576A CR11576A (es) | 2007-12-21 | 2010-07-21 | Compuestos de 1,2, 4-oxadiazol para el tratamiento de enfermedades autoinmunes |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100273770A1 (es) |
EP (1) | EP2220077A1 (es) |
JP (1) | JP2011506572A (es) |
KR (1) | KR20100108567A (es) |
CN (1) | CN101945865A (es) |
AU (1) | AU2008339993A1 (es) |
BR (1) | BRPI0821696A2 (es) |
CA (1) | CA2710055A1 (es) |
CO (1) | CO6290674A2 (es) |
CR (1) | CR11576A (es) |
DO (1) | DOP2010000193A (es) |
EA (1) | EA017669B1 (es) |
GB (1) | GB0725102D0 (es) |
IL (1) | IL206277A0 (es) |
MA (1) | MA31923B1 (es) |
NZ (1) | NZ585995A (es) |
UA (1) | UA101348C2 (es) |
WO (1) | WO2009080730A1 (es) |
ZA (1) | ZA201003965B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2012019076A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
EP2511275A1 (en) * | 2011-04-12 | 2012-10-17 | Bioprojet | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
WO2014008257A2 (en) | 2012-07-02 | 2014-01-09 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
JP2008517915A (ja) * | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
-
2007
- 2007-12-21 GB GBGB0725102.8A patent/GB0725102D0/en not_active Ceased
-
2008
- 2008-12-19 AU AU2008339993A patent/AU2008339993A1/en not_active Abandoned
- 2008-12-19 US US12/747,198 patent/US20100273770A1/en not_active Abandoned
- 2008-12-19 JP JP2010538744A patent/JP2011506572A/ja active Pending
- 2008-12-19 WO PCT/EP2008/067972 patent/WO2009080730A1/en active Application Filing
- 2008-12-19 KR KR1020107016168A patent/KR20100108567A/ko not_active Application Discontinuation
- 2008-12-19 CN CN2008801273545A patent/CN101945865A/zh active Pending
- 2008-12-19 BR BRPI0821696-7A patent/BRPI0821696A2/pt not_active IP Right Cessation
- 2008-12-19 NZ NZ585995A patent/NZ585995A/xx not_active IP Right Cessation
- 2008-12-19 EP EP08863729A patent/EP2220077A1/en not_active Withdrawn
- 2008-12-19 EA EA201070783A patent/EA017669B1/ru not_active IP Right Cessation
- 2008-12-19 UA UAA201009201A patent/UA101348C2/ru unknown
- 2008-12-19 CA CA2710055A patent/CA2710055A1/en not_active Abandoned
-
2010
- 2010-06-03 ZA ZA2010/03965A patent/ZA201003965B/en unknown
- 2010-06-10 IL IL206277A patent/IL206277A0/en unknown
- 2010-06-16 MA MA32925A patent/MA31923B1/fr unknown
- 2010-06-21 DO DO2010000193A patent/DOP2010000193A/es unknown
- 2010-06-21 CO CO10074469A patent/CO6290674A2/es not_active Application Discontinuation
- 2010-07-21 CR CR11576A patent/CR11576A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DOP2010000193A (es) | 2010-08-15 |
WO2009080730A1 (en) | 2009-07-02 |
CN101945865A (zh) | 2011-01-12 |
AU2008339993A1 (en) | 2009-07-02 |
EA017669B1 (ru) | 2013-02-28 |
BRPI0821696A2 (pt) | 2015-06-16 |
EP2220077A1 (en) | 2010-08-25 |
CO6290674A2 (es) | 2011-06-20 |
ZA201003965B (en) | 2011-03-30 |
JP2011506572A (ja) | 2011-03-03 |
CA2710055A1 (en) | 2009-07-02 |
IL206277A0 (en) | 2010-12-30 |
UA101348C2 (ru) | 2013-03-25 |
MA31923B1 (fr) | 2010-12-01 |
KR20100108567A (ko) | 2010-10-07 |
EA201070783A1 (ru) | 2010-12-30 |
NZ585995A (en) | 2012-12-21 |
US20100273770A1 (en) | 2010-10-28 |
GB0725102D0 (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11576A (es) | Compuestos de 1,2, 4-oxadiazol para el tratamiento de enfermedades autoinmunes | |
CO2021008089A2 (es) | Agonistas de glp-1r y usos de los mismos | |
UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
CR10537A (es) | Modulares del metabolismo y tratamiento de los trastornos metabolicos | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
PA8625701A1 (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
UY30812A1 (es) | Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones | |
AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
CO5570670A2 (es) | Pulmonar obstructiva cronica | |
AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
AR061967A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metil-piridin-3-il-amino)-5-metil-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos | |
AR054848A1 (es) | Agonistas del receptor de la hormona tiroidea | |
CR9667A (es) | Derivados de benzamida y usos relacionados con los mismos | |
UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
UY32343A (es) | Compuestos de oxadiazol que inhiben dgat1 | |
PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
EP1864976A4 (en) | DERIVED PROPANE-1,3-DIONE OR SALT THEREOF | |
ECSP13012600A (es) | CO-cristales y Sales de Inhibidores de CCR3 | |
CL2011002215A1 (es) | Sal de sodio cristalina de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide y psoriasica, espondilitis anquilosante, esclerosis multiple, lupus eritematoso sisttemico, psoriasis y sarcoidosis. | |
AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. | |
CR11734A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |